Companies to Develop All-in-One HIV Pill

	Tweet

In an effort to make medication regimens easier for HIV-positive patients, two drug companies have announced plans to collaborate on the first all-in-one, one-a-day pill to treat the infection.

Currently, the best AIDS treatment requires patients to take two to four pills a day. Less than a decade ago, many patients had to take 25 to 30 pills a day, often at precise times and under specific conditions such as with food, making it extremely difficult for patients to stick to the complex schedule. Missing doses makes it easier for the virus to mutate and become resistant to medication.

In the first collaboration by competing AIDS drug makers, Bristol-Myers Squibb Co. and Gilead Sciences Inc. announced Monday that they have formed a joint venture to test and market a single pill combining three widely used medicines.

Because the three individual drugs already are on the market, the once-a-day combination could be approved and on sale as early as the second half of 2006, said David Rosen, a spokesman for Bristol-Myers Squibb.

The combination pill will be made up of Sustiva, made by Bristol-Myers Squibb, and two AIDS drugs made by Gilead Sciences: Viread and Emtriva.

The latter two drugs are members of the same class of AIDS drugs, but they block copying of the AIDS virus at two different points early in its replication cycle. Sustiva is from a different class of drugs and attacks the virus later in the cycle.

The pill is for people diagnosed HIV-positive who have never taken HIV medicines before.

The two companies will have to find a way to combine the component drugs so that the single pill is absorbed the same way, has identical effects, lasts in the body as long and has the same shelf life, said Robert Lipper, vice president of biopharmaceutics research and development at Bristol-Myers.

RELATED STORIES:
Ethiopia launches free AIDS drug treatment   Budget tightening for AIDS vaccine studies   Mandela closes AIDS meeting with cry for cash   U.S. prepares plan for safe AIDS drugs to the poor   AIDS/HIV : Will America reflect world rates?   White physicians slower to prescribe HIV medications for African-Americans than for whites   Kill Aids with positive attitude   AIDS Vaccine Research Funds Getting Scarce   Reprogrammed HIV Can Hunt Down Cancer Cells   AIDS vaccine still years away, researchers say   AIDS pioneer calls for ‘therapeutic’ vaccine   Key AIDS study was deeply flawed, expert says

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]